Hemodynamic effects of N-acetylamrinone in a porcine model of group B streptococcal sepsis

Drug Metabolism and Disposition

Volumn 24, Issue 9, 1996, Pages 1028-1031

  Allen, Elizabeth M ^a,b   Rowin, Mark ^a   Pappas, Jannette B ^a   Vernon, Donald D ^a   Dean, J Michael ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; DRUG METABOLITE; N ACETYLAMRINONE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GAS ANALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEMODYNAMICS; INFUSION PUMP; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NEWBORN; NEWBORN SEPSIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; SWINE; VASODILATATION;

AMRINONE; ANIMALS; DISEASE MODELS, ANIMAL; HEMODYNAMIC PROCESSES; LUNG; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; SWINE; VASCULAR RESISTANCE; VASODILATOR AGENTS;

ANIMALIA; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS SP. 'GROUP B'; SUIDAE; SUS SCROFA;

EID: 0029833001     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. J. Edelson, T. LeJemtal, A. Alousi, C. Biddlecome, C. Maskin, and E. Sonnenblick: Relationship between amrinone plasma concentration and cardiac index. Clin. Pharmacol. Ther. 29, 723-728 (1981).
2. M. Berner, C. Jaccard, I. Oberhansli, J.-C. Rouge, and B. Friedlei: Hemodynamic effects of amrinone in children after cardiac surgery. Intensive Care Med. 16, 85-88 (1990).
3. J. Besunder and J. Blumer: Improved cardiac performance with amrinone in pediatric patients with cardiomyopathy. Crit. Care Med. 17, S101 (1989).
4. M. Kullberg, G. Freeman, C. Biddlecome, A. Alousi, and J. Edelson: Amrinone metabolism. Clin. Pharmacol. Ther. 29, 394-401 (1981).
5. E. Allen-Webb, M. Ross, J. Pappas, E. McGough, and W. Banner: Age-related amrinone pharmacokinetics in a pediatric population. Crit. Care Med. 22, 1016-1024 (1994).
6. R. Hamilton, S. Kowalsky, E. Wright, P. Cernak, D. Benziger, R. Stroshane, et al.: Effect of the acetylator phenotype on amrinone pharmacokinetics. Clin. Pharmacol. Ther. 40, 615-619 (1986).
7. A. Atkinson, T. Ruo, and A. Piergies: Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Angiology 39, 655-667 (1988).
8. M. Ratain, R. Mick, F. Berezin, L. Janisch, R. Schilsky, S. Williams, et al.: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther. 50, 573-579 (1991).
9. J. Berger, R. Gibson, W. Clarke, T. Standaert, G. Redding, W. Henderson, et al.: Effect of amrinone during group B Streptococcus-induced pulmonary hypertension in piglets. Pediatr. Pulmonol. 16, 303-310 (1993).
10. W. Meadow, B. Rudinsky, E. Strates, and K. Komar: Oxygen delivery, oxygen consumption and metabolic acidosis during GBS sepsis in piglets. Pediatr. Res. 22, 509-512 (1987).
11. R. Wetzell, B. Tabata, and M. Rogers: Hemodynamic monitoring considerations in pediatric critical care. In "Textbook of Pediatric Intensive Care" (M. Rogers, ed.), pp. 628. Williams & Wilkins, Baltimore, MD, 1992.
12. M. Ross, E. Allen-Webb, J. Pappas, and E. McGough: Amrinone-associated thrombocytopenia: pharmacokinetic analysis. Clin. Pharmacol. Ther. 53, 661-667 (1993).
13. J. Hermiller, J. Mehegan, V. Nadkarni, J. Pachall, J. Nevola, M. Fletcher, et al.: Amrinone during porcine intraperitoneal sepsis. Circ. Shock 34, 247-251 (1991).
14. 2a-induced pulmonary hypertension in dogs. Eur. Surg. Res. 26, 201-209 (1994).
15. D. Nyhan, C. Pribble, W. Peterson, K. Nishiwaki, G. Trempy, P. Desai, et al.: Amrinone and the pulmonary vascular pressure-flow relationship in conscious control dogs and following left lung autotransplantation. Anesthesiology 78, 1166-1174 (1993).
16. M. Wolfe, R. Saad, and T. Spence: Hemodynamic effects of amrinone in a canine model of massive pulmonary embolism. Chest 102, 274-278 (1992).
17. J. Edelson, T. LeJemtel, A. Alousi, C. Biddlecome, C. Maskin, and E. Sonnenblick: Relationship between amrinone plasma concentration and cardiac index. Clin. Pharmacol. Ther. 29, 723-728 (1981).
18. W. Clarke, J. Morray, K. Powers, and L. Soltow: Amrinone reduces pulmonary vascular resistance elevated with U46619 in isolated perfused lungs. J. Cardiovasc. Pharmacol. 18, 85-94 (1991).